Federico Fernandez Zelcer

Federico Fernandez Zelcer

Auto-generated profile, based on publicly available information

Federico Fernandez Zelcer

Rare Diseases Community (RDCom), Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2026 in Andes Pediatrica
Verified
Journal Article
Open access
PDF file
SSSofia Schmitt Schlindwein
Sofia Schmitt Schlindwein
EMEnzzo Barrozo Marrazzo
Enzzo Barrozo Marrazzo
LCLetícia Nunes Campos
Letícia Nunes Campos
CACarina Francisca Argüelles
Carina Francisca Argüelles
FZFederico Fernandez Zelcer
Federico Fernandez Zelcer
AGAyla Ayla Gerk
Ayla Ayla Gerk
Mucopolysaccharidosis type II (MPS II), or Hunter syndrome, is a rare lysosomal storage disorder caused by pathogenic variants in the IDS gene. This condition has specific treatment; therefore, timely diagnosis and adequate follow-up are essential for optimizing patient outcomes. Objective: To synthesize the available evidence on diagnostic and follow-up approaches for MPS II. Methods: Scoping review of ten databases for articles published between 2017 and 2022. Studies involving human participants were included if they addressed diagnostic or follow-up methods for MPS II. We followed the PRISMA-ScR guidelines and conducted qualitative analysis and descriptive statistics to identify trends in diagnostic and follow-up practices. Results: 31 articles were selected. Of these, 23 reported clinical findings, with most articles focusing on neurological (n = 17), skeletal and limbs (n = 16), and head and neck (n = 15) manifestations. Enzyme activity testing was the most reported diagnostic method, although the techniques used were frequently unspecified. Follow-up approaches included imaging studies, clinical assessments, and quality-of-life measurement scales. However, the lack of standardization in methodologies limits the generalizability of findings. Conclusion: This review highlights the need for standardized diagnostic and follow-up protocols for MPS II. Greater transparency in reporting diagnostic methods and a consistent follow-up framework are critical to improving patient care and facilitating research comparisons.

18 June 2026 in Computers in Biology and Medicine
Verified
Journal Article
Open access
LCLetícia Nunes Campos
Letícia Nunes Campos
RYRashid Benítez Yazbek
Rashid Benítez Yazbek
IRIsrael Dávila Rivera
Israel Dávila Rivera
IRIvo Valentin Rudzinski
Ivo Valentin Rudzinski
GPGabriela Oriana Pintos
Gabriela Oriana Pintos
JSJorgelina Stegmann
Jorgelina Stegmann
Clinical decision support systems (CDSS) have emerged as valuable tools for enhancing healthcare for rare diseases. Nonetheless, most tools focus on diagnosis, while few support patient monitoring. We aim to report the methods to develop an evidence-based CDSS for monitoring rare diseases, using Bardet-Biedl Syndrome (BBS) as a case study. We assembled a multidisciplinary team of over 40 healthcare providers from 11 specialities to develop rare disease monitoring plans. We conducted a scoping review to map the existing literature on BBS monitoring, followed by the systematic development of a plan framework with four sections: a tailored medical record with clinical manifestations, a multidisciplinary appointment schedule, a questionnaire tracker, and a complementary exam tracker. We extracted data from articles, books, guidelines, and point-of-care resources. We included 128 references in the analysis. Common study designs included case reports (37.5%), case series (19.5%), and cohort studies (16.4%). We documented 108 clinical manifestations of BBS across ten body systems. The multidisciplinary appointment schedule identified 24 healthcare professionals essential for BBS follow-up, and primary consultations were recommended with 13 specialities. We identified 28 scales and questionnaires, 8 sets of laboratory analyses, 7 electrophysiological studies, and 6 imaging studies for patient follow-up. Our CDSS provides a structured, evidence-based approach to monitoring BBS and improving patient outcomes. This model can be adapted for other rare diseases, promoting comprehensive and multidisciplinary patient care.